DocWire News Editors

DocwireNews

A study sought to determine whether characteristic morphologic patterns can be identified on optical coherence tomography (OCT) in eyes with age-related macular degeneration (AMD) that progress to macular atrophy (MA) and macular neovascularization (MNV).OCT volumes from patients with early or intermediate AMD in the fellow eye in the HARBOR (A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-Related Macular Degeneration) trial were included. For two years, patients underwent monthly imaging following a standardized protocol. The researchers determined the time of progression to MNV and MA and used validated artificial intelligence algorithms to automatically segment drusen and hyperreflective foci (HRF) volumes in three dimensions.There were 1,097 patients enrolled in HARBOR, of whom early or intermediate AMD in the fellow eye at baseline was observed in 518 (mean age, 78.1 years; 59.7% were female). Over 24 months of follow-up, 135 eyes (26%) developed MNV, 50 (10%) developed MA, and 333 (64%) did not progress to advanced AMD. Distinct topographic patterns were observed in drusen and HRF.Eyes progressing to MNV had a mean drusen thickness at the fovea of 29.6 &mu;m (95% confidence interval [CI], 20.2-39.0); the mean in eyes progressing to MA was 17.2 &mu;m (95% CI, 9.8-24.6), and for eyes without disease progression was 17.1 &mu;m (95% CI, 12.5-21.7). Mean drusen thickness at 0.5 mm eccentricity was 25.8 &mu;m (95% CI, 19.1-32.5) for eyes progressing to MNV, 21.7 &mu;m (95% CI, 14.6-28.8) for eyes progressing to MA, and 14.4 &mu;m (95% CI, 11.2-17.6) for eyes without disease progression. For eyes progressing to MNV, the mean HRF thickness at the foveal center was 0.072 &mu;m (95% CI, 0.000-0.152). For eyes progressing to MA, the mean HRF thickness at the foveal center was 0.059 &mu;m (95% CI, 0.000&ndash;0.126 &mu;m), and for eyes without disease progression, the mean HRF thickness at the foveal center was 0.044 &mu;m (95% CI, 0.007-0.081).Eyes progressing to MA had the largest mean HRF thickness at 0.5 mm eccentricity (0.227 &mu;m; 95% CI, 0.104-0.349) followed by eyes progressing to MNV (0.161 &mu;m; 95% CI, 0.101-0.221) and eyes without disease progression (0.085 &mu;m; 95% CI, 0.058-0.112).&ldquo;In this study, drusen and HRF represented imaging biomarkers of disease progression in AMD, demonstrating distinct topographic patterns over time that differed between eyes progressing to MNV, eyes progressing to MA, or eyes without disease progression. Automated localization and precise quantification of these factors may help to develop reliable methods of predicting future disease progression,&rdquo; the researchers concluded.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

An Analysis of Biomarkers to Identify Disease Progression in AMD

Ophthalmology

A study sought to determine whether characteristic morphologic patterns can be identified on optical coherence tomography (OCT) in eyes with age-related macular degeneration ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe